GeoVax Labs, Inc. New (GOVX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$0.3510−$0.0093 (−2.58%) on the dayAs of the close; data may be delayed.
GOVX price, last 12 months
Key stats
- Previous close
- $0.3603
- Open
- $0.3700
- Day range
- $0.3500 – $0.3785
- 52-week range
- $0.3500 – $16.80
- Volume
- 231.2K
- Avg volume (20 days)
- 352K
- Market cap
- $3.2M
Performance
1W−1.7%
1M−44.3%
3M−73.4%
6M−75.1%
YTD−91.8%
1Y−97.8%
vs S&P 500, 1Y−114.6 pts
Technicals and fundamentals
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $3.2M